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Background: JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host,
but can be reactivated under immune-compromised conditions potentially causing Progressive Multifocal
Leukoencephalopathy (PML). JCPyV encodes its own microRNA, jcv-miR-J1.
Methods: We have investigated in 50 healthy subjects whether jcv-miR-J1-5p (and its variant jcv-miR-J1a-5p) can
be detected in plasma or urine.
Results: We found that the overall detection rate of JCPyV miRNA was 74% (37/50) in plasma and 62% (31/50) in
urine. Subjects were further categorized based on JCPyV VP1 serology status and viral shedding. In seronegative
subjects, JCPyV miRNA was found in 86% (12/14) and 57% (8/14) of plasma and urine samples, respectively. In
seropositive subjects, the detection rate was 69% (25/36) and 64% (23/36) for plasma and urine, respectively.
Furthermore, in seropositive subjects shedding virus in urine, higher levels of urinary viral miRNAs were observed,
compared to non-shedding seropositive subjects (P < 0.001). No correlation was observed between urinary and
plasma miRNAs.
Conclusion: These data indicate that analysis of circulating viral miRNAs divulge the presence of latent JCPyV
infection allowing further stratification of seropositive individuals. Also, our data indicate higher infection rates than
would be expected from serology alone.
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The human JC polyomavirus (JCPyV) is the etiological
agent of Progressive Multifocal Leukoencephalopathy
(PML), a demyelinating disease of the brain caused by
lytic infection of oligodendrocytes upon viral reactivation
[1]. JCPyV is a circular double-stranded DNA virus with
very restricted cellular tropism, infecting oligodendrocytes,
astrocytes, kidney epithelial cells and peripheral blood cells
[2,3]. It is thought that infection usually occurs asymptom-
atically in childhood, after which the virus remains latent
in the body [4-6]. Under certain immunocompromising
conditions, such as treatment with immunomodula-
tory drugs (e.g. natalizumab) or infection with Human
Immunodeficiency Virus (HIV), the virus can be reacti-
vated and actively replicate into the brain, leading to PML.* Correspondence: olagatie@its.jnj.com
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unless otherwise stated.Current risk assessment for development of PML is
mainly based on the detection of antibodies against VP1,
the major capsid protein and the detection of viral DNA
in urine (viruria). It has been reported that 50 to 80% of
humans are seropositive for JCPyV and approximately one
fifth of the population sheds JCPyV in the urine [7-13].
Detection of viral DNA in plasma (viremia) is very rare
and has been shown not to be useful for predicting PML
risk [14-16]. Recently it was shown, however, that viral
DNA can be detected in CD34+ or CD19+ cells, with an
increased detection rate in Multiple Sclerosis (MS) patients
treated with natalizumab [3]. As the risk of developing
PML increases upon prolonged use of natalizumab, current
treatment guidelines recommend discontinuation of ther-
apy after the second year, particularly in JCPyV seropositive
patients [17]. Given the high prevalence of JCPyV anti-
bodies, a large number of patients are advised to discon-
tinue therapy. Although most, if not all, PML patients areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PML, the incidence of PML in natalizumab-treated MS pa-
tients is not more than 1.1% in the highest risk subgroup,
indicating that not all seropositive subjects have the same
risk of developing PML [18]. Moreover, the introduction of
a risk stratification algorithm, predominantly based on
JCPyV serology, has not led to a reduction of PML inci-
dence in natalizumab-treated MS patients [19]. Therefore,
development of new tools for improved risk stratification is
warranted, as this might justify continued therapy for many
MS patients and better identify those patients who are
really at risk of developing PML.
MicroRNAs (miRNAs) are small, non-coding RNAs
that play an important role in fine-tuning the expression
of specific gene products through translational repression
and/or mRNA degradation and as such are implicated in
many diseases [20-22]. Cellular miRNAs can also be re-
leased in small vesicles, such as exosomes and the levels of
these extracellular miRNAs in biological fluids have become
very valuable markers of several diseases, such as cancer,
Alzheimer’s disease and diabetes [23-25]. In the context of
JCPyV, it was shown that there does not appear to be a rela-
tionship between circulating human miRNAs and the pres-
ence of anti-VP1 antibodies or urinary viral load [26].
Several viruses encode their own sets of miRNAs, which
can have self-regulatory or host modulating roles [22]. Also
JCPyV, as well as other polyomaviruses, encodes its own
unique microRNA that is produced as part of the late tran-
script in an infected host cell [27,28]. These microRNAs
are thought to play an important role in controlling viral
replication through downregulation of Large T-Antigen ex-
pression, but also in controlling NKG2D-mediated killing
of virus-infected cells by natural killer (NK) cells through
downregulation of the stress-induced ligand ULBP3 [28,29].
The diagnostic potential of circulating viral miRNAs
has already been investigated for Epstein-Barr virus and
Kaposi’s sarcoma-associated herpesvirus (KSHV), where
they might represent potential markers for virus associated
malignancies [30,31]. Also JCPyV miRNA has been shown
recently to be a useful biomarker for JCPyV infection in the
gastrointestinal tract [32]. In this study we have investigated
whether JCPyV-encoded miRNAs could be detected in
plasma or urine of healthy subjects and whether the
presence of these miRNAs was related to VP1 serology
or urinary viral load. We demonstrate that these viral
miRNAs can indeed be detected in plasma or urine and
that they might be useful markers for JCPyV infection.
Results
Assay linearity and specificity
Plasma or urine levels of JCPyV miRNA were analyzed
using stem–loop RT followed by TaqMan PCR analysis
[33]. Since the 3p miRNA of JCPyV is identical to the 3p
miRNA of BKPyV, only 5p miRNAs were investigated [28].As we previously identified a variant of the JCV-miR-J1-5p
bearing one nucleotide difference compared to the miRNA
described in miRBase (designated JCV-miR-J1a-5p), assays
specifically designed for both variants were used, as well as
an assay detecting the closely related BKPyV 5p miRNA
(Figure 1A-C) [26]. To evaluate the specificity of the assays,
standard curves were prepared of each miRNA (JCV-miR-
J1-5p, JCV-miR-J1a-5p and BKV-miR-B1-5p) and analyzed
using the three specific assays (Figure 1D-F). Relative
detection efficiency was calculated from the difference
of quantification cycle (Cq) between the specific assay
and the non-specific assay, using samples containing
2.104 copies/μL of the individual miRNAs (Figure 1G).
Only marginal cross reaction was observed for most
combinations, but a substantial cross reaction was observed
between JCV-miR-J1a-5p and BKV-miR-B1-5p. Therefore,
for every single clinical sample (plasma or urine), the
contribution of non-specific amplification was calculated
based on these standard curves. For JCV-miR-J1-5p and
JCV-miR-J1a-5p it was confirmed that the contribution of
non-specific signal was negligible compared to the specific
signal (Additional file 1: Table S1 and Additional file 2:
Figure S1). For the BKV-miR-B1-5p assay, however, the
calculated contribution of JCV-miR-J1a-5p in most cases
was similar to the measured levels, indicating that the
BKV-miR-B1-5p assay in most cases actually was detect-
ing JCV-miR-J1a-5p. Consequently, we can conclude that
in most samples BKV-miR-B1-5p is absent or present at
such low levels that it does not interfere in the interpret-
ation of the JCV-miR-J1-5p and JCV-miR-J1a-5p analyses.
Analysis of JCPyV miRNA levels in plasma and urine
Plasma and urine samples were collected from 50 healthy
subjects (HS) and JCPyV VP1 serology and both plasma
and urinary viral load was determined (Additional file 3:
Table S2). Based on these parameters, subjects were catego-
rized as Ab-, Ab+VL- or Ab+VL+ (Table 1). Among these 50
HS JCPyV VP1 antibody prevalence was 72% (36/50) and
36% (13/36) of this group were also shedding virus in
their urine, representing 26% (13/50) of the total study
population. In the JCPyV VP1 seronegative group, no
urinary virus shedding was observed. We found no sub-
jects with detectable JCPyV DNA in plasma, similar to
previous observations [16].
Total RNA, including microRNAs was isolated from
both urine and plasma and the level of JCPyV 5p miRNA
was quantified in all samples (Figure 2). The overall detec-
tion rate of JCPyV miRNA was 74% (37/50) in plasma and
62% (31/50) in urine (Figure 3A). Further analysis of
the different subgroups shows that JCPyV miRNA was
detected in plasma or urine from HS from all subgroups
(Ab-, Ab+ VL- or Ab+VL+) at similar detection rates
(P > 0.05 between the subgroups for both plasma and urine).
In the seropositive group, JCPyV 5p miRNA was detected
Figure 1 Validation of the stem-loop RT-PCR miRNA assays. (A) Genomic location of the JCPyV/BKPyV encoded miRNAs. (B) Graphical
representation of a pre-miRNA as precursor of the mature 5p and 3p miRNAs generated upon cleavage by Dicer (C) Sequence comparison of the
three miRNAs investigated. (D-F) The assay linearity and specificity was evaluated with dilution series of three synthetic miRNAs, miR-J1-5p,
miR-J1a-5p and miR-B1-5p. Each dilution series was analyzed using the three miRNA assays. (G) The assay readings of miR-J1-5p by miR-J1-5p
assay, miR-J1a-5p by miR-J1a-5p assay, and miR-B1-5p by miR-B1-5p assay at concentration levels of 2.104 copies/μL extract were used as the
relative standards (100%) for the analysis of assay cross-reactivity.
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(23/36) of subjects. Remarkably, also in the seronegative
group, JCPyV 5p miRNA was detected in plasma of
86% (12/14) of subjects and in urine of 57% (8/14) of
subjects. These detection rates were not statistically
different compared to those in seropositive subjects
(P > 0.05 both for plasma and urine).
Quantitative analysis of JCPyV 5p miRNA indicated
plasma levels of JCPyV 5p miRNA were similar in the
three different subgroups (Figure 3C). In urine, significantly
higher levels (P < 0.001) were observed in the subgroup
shedding JCPyV in their urine compared to the subgroupnot shedding JCPyV in their urine (Figure 3D). No cor-
relation was observed between plasma levels and urine
levels of JCPyV 5p miRNA (Figure 3B). Remarkably,
while in plasma higher levels of JCV-miR-J1-5p were
detected than JCV-miR-J1a-5p, in urine both variants
were detected at similar levels (Figure 2). Also, the identity
of the miRNAs (J1 or J1a variant) was not correlated be-
tween urine and plasma. Comparison of JCPyV 5p miRNA
levels with JCPyV VP1 serology or urinary viral load
showed that, specifically in the subgroup of JCPyV shed-
ders (Ab+VL+) a good correlation (P < 0.005, r = 0.78) ex-
ists between miRNA levels and antibody levels, as well as
Table 1 Overview of subjects investigated
Variable Healthy subjects
(n = 50)
Gender, n (%)
Male 22 (44%)
Female 28 (56%)
Age, median (Min-Max) 40.5 (23-59)
Race, ethnicity, n (%)
White 38 (76%)
Black 3 (6%)
Asian 8 (16%)
Other/unknown 1 (2%)
VP1 serology, n (%)
Positive 36 (72%)
Negative 14 (28%)
Viruria, n (%)
Positive* 13 (26%)
Negative 37 (74%)
Viremia, n (%)
Positive 0 (0%)
Negative 50 (100%)
*All viruric subjects were part of the VP1 seropositive subgroup.
Figure 2 Individual levels of jcv-miR-J1-5p and jcv-miR-J1a-5p in plas
JCPyvV miRNA variants (jcv-miR-J1-5p and jcv-miR-J1a-5p) in every individu
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viral load (Figure 4A-B). No correlation could be ob-
served between plasma miRNA levels and any other
parameter analyzed (Figure 4C-D).
Discussion
Although JCPyV is known to be the etiological agent re-
sponsible for development of PML, it is also well-known
that this polyomavirus is widely distributed in the human
population without any clinical manifestation [1]. In this
study we have analyzed the level of the viral miRNAs in
plasma and urine of healthy subjects. As is the case for
other polyomaviruses, JCPyV encodes a pre-miRNA that
is further processed into the mature 5p and 3p miR-J1s.
The pre-miRNA is encoded on the late strand of the viral
genome and is shown to be expressed concurrently with
the late mRNA transcript, thereby downregulating early
transcript [27,28]. The presence of viral miRNAs might
therefore be considered as a marker for latent infection.
Since BKPyV and JCPyV share the same 3p miRNA, only
the 5p miRNAs were included in this study [28].
We showed that most of the healthy subjects have
low, but well-detectable levels of viral miRNAs in total
RNA extracts of plasma or urine, even in subjects that
are seronegative and as such considered not to be infected.
This finding indicates that the analysis of antibodies against
JCPyV VP1 is insufficient to identify all infected individuals.
Previous studies also identified individuals that were sero-
negative but clearly infected based on the fact that they
were viremic in specific cell compartments (CD34+ cells) orma and urine. Plasma and urine levels (in log copies/mL) of the two
al subject.
Figure 3 JCPyV miRNA levels detected in plasma and urine of healthy subjects, categorized based on serology and urinary viral load.
(A) Number of subjects with detectable levels of JCPyV miRNAs in plasma and urine in the different groups. (B) Correlation between plasma and
urine levels (in log copies/mL) of JCPyV miRNAs. (C) Plasma levels (in log copies/mL) of JCPyV miRNAs in the different groups. In case both
variants were detected, the sum of both levels is presented. (D) Urine levels (in log copies/mL) of JCPyV miRNAs in the different groups. In case
both variants were detected, the sum of both levels is presented.
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number of seronegative subjects was found to be infected,
our analysis of viral miRNAs in plasma and urine identified,
respectively 12 and 8 out of 14 seronegative individuals
to be infected with JCPyV. Only 1 seronegative subject
was found to be negative for both plasma and urine viral
miRNAs. These data suggest that JCPyV is capable of
evading immune recognition by the host’s humoral im-
mune system and residing latently in the body, with viral
miRNAs leaking in the blood or urine as a silent witness of
this latent activity.
Similar to the findings in seronegative subjects, also a
large group of seropositive subjects was found to have
viral miRNAs in plasma or urine. 69% of seropositive
subjects were positive for plasma viral miRNAs and 64%
were found to be positive for urinary viral miRNAs.
Given the fact that viral miRNAs can only be produced
upon ongoing viral transcription in infected host cells,
whereas serology rather discloses information on expos-
ure to the virus and more in particular the response of
the humoral immune system towards this exposure, the
analysis of viral miRNAs in seropositive subjects might
add another level to the risk prediction algorithms for
PML development. We therefore suggest that further
studies would be performed to investigate the potentialof viral miRNA levels in plasma or urine as a risk marker
for PML development.
Plasma levels of viral miRNAs in seropositive subjects
were not different compared to seronegative subjects
and both were close to the detection limit, indicating
that in healthy subjects only low activity of JCPyV is
present in the periphery, independent of their antibody
status. In contrast, we found significantly increased urin-
ary viral miRNA levels in shedders. In this group of viral
shedders, there was also a strong correlation between
urinary miRNA levels and anti-VP1 antibody levels or
urinary viral load.
Besides the discordance between urine and plasma
miRNA levels, also the identity of the detected miRNAs
(J1-5p or J1a-5p variant) within individual subjects was
different in plasma and urine. The most obvious explan-
ation for these observations would be that two independent
viral propagation zones exist in one individual: one in bone
marrow cells, blood cells and perhaps also brain cells
(Bone-Blood-Brain) and a second one in urinary tract cells.
This hypothesis is also supported by other work where se-
quencing analysis of the VP1 gene and/or non-coding con-
trol region (NCCR) in samples obtained from PML patients
showed a similar dichotomy between urine on the one hand
and plasma and cerebrospinal fluid (CSF) on the other hand
Figure 4 Viral miRNAs related to other viral parameters. (A) Correlation between JCPyV miRNA levels (in log copies/mL) in urine and JCPyV
VP1 serology (in log2 test/ctrl). Shedders are indicated in red and P-value and r value are based on this subset only. (B) Correlation between
JCPyV miRNA levels (in log copies/mL) in urine and JCPyV urinary viral load (in log copies/mL) in shedders. (C) Correlation between JCPyV miRNA
levels (in log copies/mL) in plasma and JCPyV VP1 serology (in log2 test/ctrl). Shedders are indicated in red and P-value is based on this subset
only. (D) Correlation between JCPyV miRNA levels (in log copies/mL) in plasma and JCPyV urinary viral load (in log copies/mL) in shedders.
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zones exists, is unclear and remains to be investigated.
We found that increased viral multiplication in the
urinary propagation zone, as determined by increased
urinary viral load, is accompanied by an increased level
of urinary viral miRNAs. This might at first sight appear
in contradiction with the observation that polyomavirus
miRNAs, including JCPyV, have been shown to down-
regulate expression of large T-antigen and to suppress
viral replication [28,40-42]. One might therefore assume
that an increased level of viral miRNAs would be associ-
ated to a lower viral load. This mechanistic model does
however not exclude that in subjects with high urinary
viral load, viral miRNAs are released at increased levels
as a consequence of high virion production, a process
that requires transcription of the late transcript, which
also encodes the miRNAs. Furthermore, several studies
have shown that infectivity of mutant viruses lacking the
viral miRNAs are not impacted, again indicating that in-
creased levels of viral miRNAs are not per se associated
with decreased virion production in vivo [28,43]. On the
other hand, these miRNAs can also be produced and re-
leased from an infected cell without the need for activeviral replication, as is also the case for Herpes Simplex
Virus and Epstein-Barr Virus during latent infection
[44-46]. This would in fact also explain why no viral
DNA can be detected in plasma of healthy subjects,
while viral miRNAs are detectable in a large number of
these subjects. Taken together, low levels of circulating
viral miRNAs would serve as biomarker for latent JCPyV
infection and increased levels might be indicative of
increased viral activity. This raises the question whether
an increased viral multiplication in the bone-blood-brain
propagation zone, as is the case in PML patients, also is
accompanied by an increase in plasma viral miRNAs.
Therefore, it would be of great interest to determine
miRNA levels in plasma of PML patients, but even more
to assess in longitudinal studies whether plasma miRNA
levels in MS patients treated with natalizumab increase
over time and as such might serve as a monitoring tool
for viral reactivation. Similar studies have been performed
for the closely related BKPyV in the context of kidney
transplant patients developing polyomavirus-associated
nephropathy (PVAN) and found strongly increased levels
of miR-B1-5p in urine from patients with PVAN [42].
Also, a strong correlation appears to exist between BKPyV
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renal transplant patients [47].
Since the three miRNAs analyzed in this study are very
similar, the cross-reactivity of the different assays was
evaluated using synthetic miRNAs. Although we believe
that we have provided sufficient evidence that the de-
tected levels of JCPyV miRNAs are specific for JCPyV, it
cannot be excluded that the assays used are prone to
some non-specific amplification of other miRNAs. How-
ever, no miRNAs with nucleotide sequence resembling
the sequence of jcv-miR-J1-5p have been registered in
miRBase 21, except for bkv-miR-B1-5p [48]. It can also
not be excluded that other, unknown human polyoma-
viruses exist that encode an identical or closely related
miRNA that is detected in our assays.
Conclusions
Based on the work described here, we conclude that JCPyV
miRNAs can be detected in plasma and urine of healthy
subjects, allowing further stratification of seropositive indi-
viduals. Furthermore, our data indicate higher infection
rates than would be expected from serology alone.
Materials and methods
Ethics statement
The Ethics Committee [“Commissie voor Medische
Ethiek - ZiekenhuisNetwerk Antwerpen (ZNA) and
the Ethics committee University Hospital Antwerp]
approved the Protocol, and Informed consent, which
were signed by all subjects.
Healthy subject samples
A total of 50 healthy subjects (HS) were recruited in
Belgium for this study [10,26,49]. The demographic de-
scription of the HS population is presented in Table 1.
Plasma samples and urine samples were collected from all
these HS and stored at −80°C until further processing.
JC polyomavirus viral load assay
Analysis of the urinary viral load was performed as de-
scribed previously [10]. Analysis of the plasma viral load
was performed similarly, with the exception that 200 μL
plasma was used for DNA extraction.
JC polyomavirus VP1 serology assay
The anti-JCPyV antibody assay was performed as described
earlier [26]. Samples were considered positive if OD values
were higher than 2-fold the OD value of the blank sample
(i.e. log2 test/ctrl > 1).
Synthetic microRNA molecules and generation of miRNA
standard curves
Three RNase-free 5’-phosphorylated miRNA oligoribonu-
cleotides were synthesized (Integrated DNATechnologies)for the validation of the miRNA assays, corresponding to
jcv-miR-J1-5p (5’-phospho-UUCUGAGACCUGGGAA
AAGCAU-OH-3’), jcv-miR-J1a-5p (5’-phospho-UUCUGA
GACCUGGGAAGAGCAU-OH-3’) and bkv-miR-B1-5p
(5’-phospho-AUCUGAGACUUGGGAAGAGCAU-OH-3’).
Stock solutions of 100 μM synthetic oligonucleotide in
RNase-free and DNase-free water were prepared according
to the concentrations and sample purity quoted by the
manufacturer (based on spectrophotometric analysis).
These stock solutions were diluted to a concentration of
approximately 3.32 pM, corresponding to 2.105 copies/μL.
A total of six serial 10-fold dilutions were prepared, starting
from 2.105 copies/μL down to 2 copies/μL and additional
no template controls (NTC; zero copies) were examined.
Dilution series of each of the synthetic miRNAs were made
in RNase-free and DNase-free water.
Analysis of viral miRNAs
Levels of circulating viral miRNAs were determined by
means of quantitative reverse transcriptase PCR (qRT-PCR)
with hydrolysis probe based miRNA assays, purchased from
Life Technologies. Specific assays were used for jcv-miR-J1-
5p (Assay ID 007464_mat), jcv-miR-J1a-5p (Custom Assay
ID CS39QVQ) and bkv-miR-B1-5p (Assay ID 007796_mat).
As extraction and reverse transcription efficacy control,
assays specific for human miRNAs hsa-miR-26a (assay ID
000405), hsa-miR-30b (assay ID 002129) and mmu-miR-
93 (assay ID 001090) were included in the analysis.
Briefly, RNA was isolated from 200 μL plasma or
urine using the miRNeasy kit (Qiagen) according to
the manufacturer’s instructions. Three μL of total RNA
(representing 20% of total RNA extract) or synthetic
miRNA solution was reverse transcribed using the pooled
RT stem-loop primers (Life Technologies), enabling miRNA
specific cDNA synthesis. Subsequently, 2.5 μL of the RT
product (representing 1/6 of total RT product) was pre-
amplified by means of a 12-cycle PCR reaction with a
pool of miRNA specific forward primer and universal
reverse primer to increase detection sensitivity. Diluted
(1:8) pre-amplified miRNA cDNA was then used as in-
put for a 45-cycle qPCR reaction with miRNA specific
hydrolysis probes and primers (Life Technologies). For
analysis of the viral miRNAs, 2 μL of input was used.
For analysis of the human miRNAs, 2 μL of input was used
for urine derived miRNAs and 0.2 μL was used for plasma
derived miRNAs. All reactions were performed in duplicate
on the LightCycler® 480 instrument (Roche Applied Science).
Quantification cycle (Cq) values were calculated using the
2nd Derivative method with a detection cut-off of 40 cycles.
Only samples with quantifiable Cq values for both duplicates
were considered positive. Absolute miRNA levels in plasma
or urine were calculated based on the standard curves for
each specific miRNA assay. Limit of quantification (LOQ)
was defined as the miRNA concentration corresponding
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specific miRNA. For each sample, average Cq value
of the 3 human control miRNAs was calculated and
possible outliers were identified using Grubbs’ test
(using a significance level of 0.05). In case outliers were
detected, results of the corresponding viral miRNAs were
not included for further analysis.Statistical analysis
Differences in relative occurrence of viral miRNAs between
groups were assessed using a Fisher’s test. Differences
between groups were considered statistically significant
at P < 0.05. Differences in miRNA levels between groups
were assessed using a Mann-Whitney test. Differences
between groups were considered statistically significant
at P < 0.05. Correlation between different parameters
was analyzed using linear regression. P-value was calcu-
lated to determine whether slope was significantly non-
zero and strength of correlation was determined using
r-value. All statistical analyses were performed using
GraphPad Prism v 5.04.Additional files
Additional file 1: Table S1. Calculated contributions of non-specific
detection. Based on the calibration curves for each specific assay, the
concentration of the specific miRNA in every sample is calculated. Based
on that concentration and the calibration curves for the non-specific
assays, a calculated Cq value is then determined for each of the other
assays. In case this calculated Cq value is higher than 40, it is assumed
that there is no contribution of non-specific detection of that particular
miRNA in that particular assay. This approach is also visually presented in
Additional file 2: Figure S1.
Additional file 2: Figure S1. Calculation of the contribution of
non-specific detection. Based on the standard curves the contribution of
non-specific detection of a miRNA on the Cq value of another miRNA
assay is calculated. First, based on the Cq value obtained from the
specific assay and its specific standard curve, the miRNA level is
quantified (indicated by “1”). Subsequently, it is calculated what the Cq
value would be in the non-specific assays using extrapolation of the
non-specific standard curves (indicated by “2”).
Additional file 3: Table S2. Individual results of JCPyV VP1 antibody
levels, urinary viral load and plasma viral load.
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